Contents
low permeability. But the choice of primary packaging can never be taken lightly, as Elly Earls discovers from Hanns-Christian Mahler, chief enablement officer at contract development and manufacturing organisation, ten23 health.
33 A new reliable process for type 2 glass vials Stoelzle Glass Group
Supply chain & logistics
34 Good things, small packages Andrea Valentino talks to Patricia Turney, senior vice president of operations at Arcutis Biotherapeutics, to understand why the pharma supply chain has grown in importance over recent years, the limitations of traditional drug containers – and what the so-called hybrid model could mean for both drug delivery and the planet.
37 Smart pharmaceutical transportation Turkish Cargo
38 Transporting hope to South America LATAM Cargo
40 The struggle to supply Pharmaceutical supply chains are still reacting to the pressures of the pandemic, though they have mostly held steady and avoided many of the potential risks. The stresses placed on certain products have led both commercial and academic experts to
44
ask how we might add even more protection for companies, hospitals and patients that rely on timely deliveries. From enhancing visibility to localised sourcing, Jim Banks explores how the industry can instil more reliability in its supply chains.
43 The fight against pharma counterfeits SIPCA
Chemicals & raw materials 44 Double agents
Looking at a vial of liquid or a solid pill, it’s easy to see pharmaceuticals as simple objects rather than a complex array of chemicals and raw materials, delicately balanced to achieve a desired effect. The current coronavirus vaccines are a good example of such a balance, with the list of ingredients including water, sugar and salt, all of which play a
different role in the effective deployment of the messenger RNA (mRNA) that stimulates the immune response. But one category of components has held the spotlight recently for its ability to improve the protection offered by vaccines. Monica Karpinski looks at the role adjuvants play in making vaccines effective, as well as the research that suggests they could hold even greater unrealised potential.
47 Reuniting the fine and speciality community Chemspec Europe 2022
Outsourcing 48 World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
48 Outsource and intake For decades, pharmaceutical companies have relied on contract development and manufacturing companies (CDMOs) to develop drugs. But though these third-party contractors proved their worth in the fight against Covid, dramatically expanding global vaccine manufacturing capacity, a consequence has been that the supply of other medicines has suffered. Andrea Valentino talks to Joe Glajch, an industry veteran and consultant, and Emily Thompson, US director for new process technology at DPS Group to understand the historical importance of CDMOs, why the pandemic has put their role under scrutiny – and whether recent experiences could result in a more fundamental shift in the manufacturing of drugs.
7
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
